Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value
$26.47−2.60 (-8.94%)
Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –
Zymeworks ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
No ebitda figures for Zymeworks
Zymeworks has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?